These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Bioidentical hormone therapy: a review of the evidence. Cirigliano M J Womens Health (Larchmt); 2007 Jun; 16(5):600-31. PubMed ID: 17627398 [TBL] [Abstract][Full Text] [Related]
27. Bioidentical hormones for menopausal therapy. Sites CK Womens Health (Lond); 2008 Mar; 4(2):163-71. PubMed ID: 19072518 [TBL] [Abstract][Full Text] [Related]
28. Potential risks of pharmacy compounding. Gudeman J; Jozwiakowski M; Chollet J; Randell M Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368 [TBL] [Abstract][Full Text] [Related]
29. Pharmacy compounding of high-risk level products and patient safety. Mullarkey T Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449 [TBL] [Abstract][Full Text] [Related]
30. Hospital Compounding in Nigeria: A Review of Needs, Practice, and Suggestions for Pharmaceutical Dispensing Ciurriculum Development. Orubu ESF; Patani BO; Arhewoh MI Int J Pharm Compd; 2021; 25(6):475-481. PubMed ID: 34807842 [TBL] [Abstract][Full Text] [Related]
31. Compounding for animal patients: contemporary issues. Lust E J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248 [TBL] [Abstract][Full Text] [Related]
33. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. Santoro N; Braunstein GD; Butts CL; Martin KA; McDermott M; Pinkerton JV J Clin Endocrinol Metab; 2016 Apr; 101(4):1318-43. PubMed ID: 27032319 [TBL] [Abstract][Full Text] [Related]
34. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Holtorf K Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815 [TBL] [Abstract][Full Text] [Related]
35. Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use. L'Hermite M Climacteric; 2017 Jun; 20(3):205-211. PubMed ID: 28509626 [TBL] [Abstract][Full Text] [Related]
36. Compounded medicines and 'off label' prescribing - a case for more guidance. Fois RA; Mewes BT; McLachlan AJ; Ramzan I Aust Fam Physician; 2009; 38(1-2):16-20. PubMed ID: 19283230 [TBL] [Abstract][Full Text] [Related]
37. Compounding for women's health: a compounder's perspective - need, regulations, and future. Boomsma D; Lahoud G Climacteric; 2021 Feb; 24(1):32-37. PubMed ID: 33135943 [TBL] [Abstract][Full Text] [Related]
38. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes. Isles M Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874 [TBL] [Abstract][Full Text] [Related]